Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Stock Information for Vor Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vor Biopharma Inc.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease
Vor Bio Announces $75 Million Private Placement with TCGX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.